X4 Pharmaceuticals Inc (XFOR) Stock Price, Quote & News

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 529 8300

Website: www.x4pharma.com

Address:

61 North Beacon Street, 4th Floor, Boston, United States

Duskfall Mar. 20 at 4:18 PM

$XFOR Niceee 👍

0 · Reply

captainjoerg Mar. 20 at 3:01 PM

$OCGN good that my $XFOR is running

0 · Reply

Duskfall Mar. 20 at 2:51 PM

$XFOR 📈✅

0 · Reply

Duskfall Mar. 20 at 2:29 AM

$XFOR Shall we go up to five dollars now?

0 · Reply

MrFister1661 Mar. 19 at 11:53 PM

$XFOR been waiting for this one, averaged in at $1.82 over last summer. New leadership has been really good and I'm excited for this to progress

0 · Reply

MaddyLeo Mar. 19 at 11:00 PM

$XFOR top recommendation by Chat Gpt , ctalyst coming soon

0 · Reply

MaddyLeo Mar. 19 at 10:25 PM

$XFOR i think i m early here🙈🙈

0 · Reply

OfficialStocktwitsUser Mar. 19 at 1:12 AM

$XFOR RSI: 61.17, MACD: 0.1309 Vol: 0.43, MA20: 3.66, MA50: 3.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Love_To_Learn Mar. 18 at 11:11 AM

$DTIL $AMTX $XFOR been raising u up and lately $LNZA

0 · Reply

FoxyDreams Mar. 17 at 9:20 PM

*@SqueezeSharkie is on another level, outperforming 90% of traders on this platform. *If you’re not following yet, you’re leaving value on the table. Takes 2 seconds and it’s free. 💎 $ALOY $CYCU $XFOR $LIDR ^^ on watch.

1 · Reply

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 4, 2026, 7:00 AM EST - 17 days ago

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

Mar 3, 2026, 10:04 AM EST - 18 days ago

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

Mar 2, 2026, 4:30 PM EST - 19 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2026, 7:00 AM EST - 22 days ago

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Feb 16, 2026, 5:57 PM EST - 4 weeks ago

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 3, 2026, 7:00 AM EST - 6 weeks ago

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

Dec 1, 2025, 9:09 AM EST - 3 months ago

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

Nov 5, 2025, 4:01 PM EST - 4 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 4 months ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 27, 2025, 7:05 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 24, 2025, 12:37 AM EDT - 5 months ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Sep 17, 2025, 7:00 AM EDT - 6 months ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Aug 15, 2025, 4:05 PM EDT - 7 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 7:00 AM EDT - 7 months ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 12, 2025, 7:00 AM EDT - 7 months ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Jun 16, 2025, 8:00 AM EDT - 9 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 10, 2025, 8:00 AM EDT - 10 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

May 14, 2025, 4:12 PM EDT - 11 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 1, 2025, 12:44 PM EDT - 11 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:01 AM EDT - 11 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 28, 2025, 7:16 AM EDT - 11 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

Apr 24, 2025, 8:03 AM EDT - 11 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:00 AM EDT - 11 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

Mar 25, 2025, 3:02 PM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Feb 19, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 6, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Jan 24, 2025, 7:36 AM EST - 1 year ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 13, 2024, 9:31 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 13, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 9, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 7, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 29, 2024, 5:02 PM EDT - 2 years ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 6:37 AM EDT - 2 years ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Duskfall Mar. 20 at 4:18 PM

$XFOR Niceee 👍

0 · Reply

captainjoerg Mar. 20 at 3:01 PM

$OCGN good that my $XFOR is running

0 · Reply

Duskfall Mar. 20 at 2:51 PM

$XFOR 📈✅

0 · Reply

Duskfall Mar. 20 at 2:29 AM

$XFOR Shall we go up to five dollars now?

0 · Reply

MrFister1661 Mar. 19 at 11:53 PM

$XFOR been waiting for this one, averaged in at $1.82 over last summer. New leadership has been really good and I'm excited for this to progress

0 · Reply

MaddyLeo Mar. 19 at 11:00 PM

$XFOR top recommendation by Chat Gpt , ctalyst coming soon

0 · Reply

MaddyLeo Mar. 19 at 10:25 PM

$XFOR i think i m early here🙈🙈

0 · Reply

OfficialStocktwitsUser Mar. 19 at 1:12 AM

0 · Reply

Love_To_Learn Mar. 18 at 11:11 AM

$DTIL $AMTX $XFOR been raising u up and lately $LNZA

0 · Reply

FoxyDreams Mar. 17 at 9:20 PM

1 · Reply

1nvestorGadget Mar. 17 at 7:20 PM

$XFOR what’s guidance? Great job with the new team.

0 · Reply

pc247cz Mar. 17 at 6:16 PM

$XFOR 💪

0 · Reply

Love_To_Learn Mar. 17 at 5:37 PM

$DTIL $XFOR CONTINUED TO PUSH U 2 UP

0 · Reply

PensionPulse Mar. 17 at 4:34 PM

$XFOR Fidelity, Perceptive in this, they manage their book well, keep an eye on it.

0 · Reply

Love_To_Learn Mar. 17 at 2:43 PM

$XFOR $DTIL !

0 · Reply

mebanks Mar. 17 at 2:28 PM

$XFOR ; funded through to 2028, "X4 Pharmaceuticals gets EMA CHMP positive opinion backing EU approval of mavorixafor for WHIM syndrome Reported fiscal Q4 2025 non-GAAP EPS of $-0.22, a 96% YoY improvement, beating analyst estimates Fiscal Q4 2025 revenue was $2.6M, up 79% YoY, also ahead of revenue estimates"

0 · Reply

DonCorleone77 Mar. 17 at 11:27 AM

$XFOR X4 Pharmaceuticals sees cash runway through 2028 Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028.

0 · Reply

DonCorleone77 Mar. 17 at 11:26 AM

$XFOR X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c) Reports Q4 revenue $2.6M, consensus $1.73M. "Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "We have sharpened our operational focus and implemented targeted initiatives to drive continued progress in 4WARD with enrollment on track for completion in the third quarter of this year. Additionally, we were pleased to receive the positive opinion from the European Medicines Agency recommending the potential European approval of mavorixafor in WHIM syndrome, which would be the first and only therapy in Europe to treat this devastating condition."

0 · Reply

TwongStocks Mar. 17 at 11:16 AM

$XFOR PR just released https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025

0 · Reply

TwongStocks Mar. 17 at 11:15 AM

$XFOR 10-K filed this morning. I do not see any PRs yet. https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000150169726000018/xfor-20251231.htm • 90,919,696 shares outstanding as of Mar 12 • For fiscal year 2025, they generated $27.6M in license revenue. Net product sales for XOLREMDI was $2.27M in Q4 and $6.52M for full year 2025. • $253 in cash and cash equivalents at end of 2025. They believe they have enough cash to fund operations into 2028. • 4WARD phase 3 trial expected to complete enrollment in Q3 2026, topline data expected in 2H 2027.

0 · Reply

Sandeep150 Mar. 12 at 8:45 PM

$XFOR same there where it started. It dying

0 · Reply

EldarGman Mar. 11 at 3:25 PM

$PAVS short interest- 64,35% of the public float!!!🚀🚀🚀buy and hold!!!💪 $HIMS $ROLR $XFOR

1 · Reply

Market Cap	389.14M
Revenue (ttm)	2.56M
Net Income (ttm)	-37.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,462.89%
Debt to Equity Ratio	1.23

Volume	684,900
Avg Vol	506,316
Day's Range	N/A - N/A
Shares Out	90.92M
Stochastic %K	58%
Beta	0.43
Analysts	Strong Sell
Price Target	$10.00